Liquidia, Shake Shack And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 19 2024
0mins
Should l Buy LQDA?
Source: Benzinga
U.S. Stock Market Overview: U.S. stock futures showed slight gains, with S&P 500 futures up about 0.1%, while several companies like Liquidia Corporation and YXT.COM Group experienced significant pre-market losses.
Notable Stock Movements: Liquidia's shares dropped 36.3% after FDA approval of its inhalation powder; other notable declines included Mereo BioPharma down 14.8% and Shake Shack downgraded by an analyst, falling 3.6%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LQDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LQDA
Wall Street analysts forecast LQDA stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 39.470
Low
31.00
Averages
47.50
High
67.00
Current: 39.470
Low
31.00
Averages
47.50
High
67.00
About LQDA
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Liquidia CEO Indirectly Sells 53,300 Shares
- Indirect Share Sale: Liquidia's CEO Roger Jeffs indirectly sold 53,300 shares through Serendipity BioPharma LLC, generating approximately $2.14 million, indicating the company's agility in capital management.
- Updated Holdings: Following this transaction, Liquidia's direct and indirect holdings stand at 1,137,599 and 1,441,934 shares respectively, reflecting management's continued confidence in the company's future direction.
- Strong Yutrepia Sales: Liquidia's dry inhalable treprostinil drug, Yutrepia, achieved an annualized sales figure of $360.4 million in Q4 2025, demonstrating market acceptance that exceeded expectations and enhancing the company's profitability.
- Future Development Potential: Liquidia is developing an extended-release formulation of treprostinil, L606, which is currently in pivotal studies; if successful, this could further solidify its market position in pulmonary hypertension treatments.
See More
Liquidia CEO Indirectly Sells 53,300 Shares, Raising $2.14 Million
- Transaction Overview: Liquidia's CEO Roger Jeffs indirectly sold 53,300 shares through Serendipity BioPharma LLC, generating approximately $2.14 million, indicating a continued preference for liquidity management through indirect vehicles.
- Holding Change Analysis: The 53,300 shares sold represent 2.02% of total holdings and 3.56% of indirect holdings, reflecting a measured reduction while maintaining a substantial direct ownership value of around $47.10 million.
- Transaction Context: This sale was executed under a Rule 10b5-1 plan, classifying it as a routine, pre-scheduled liquidity event rather than a discretionary market-timed action, which reflects management's confidence in the company's future.
- Product Performance Highlights: Liquidia's Yutrepia achieved annualized sales of $360.4 million in Q4 2025, with a net income of $14.6 million, showcasing strong market performance in the pulmonary arterial hypertension treatment space, further bolstering investor confidence.
See More
Liquidia CFO Sells Significant Shares
- Executive Sell-off: On April 9, 2026, Liquidia's CFO and COO, Michael Kaseta, sold 133,789 shares of the company, totaling $5,383,38, which may raise concerns about the company's future outlook among investors.
- Market Reaction: Such executive sell-offs are often perceived as negative signals for stock performance, potentially leading to a decline in investor confidence in Liquidia and affecting its stock price.
- Shareholding Structure Change: Kaseta's sell-off could alter Liquidia's shareholder structure, especially if executive ownership is significant, raising questions about corporate governance and management stability.
- Future Outlook: While the sell-off may cause market fluctuations, investors should continue to monitor Liquidia's fundamentals and future strategic direction to assess its long-term investment value.
See More
Liquidia CEO Sells Shares
- Executive Sell-off: Liquidia's CEO Roger Jeffs sold 25,000 shares on April 9, 2026, which may raise concerns about the company's future prospects, as executive sell-offs are often interpreted as a lack of confidence in the company's performance.
- Market Reaction: This sell-off could lead to a decline in investor trust in Liquidia, potentially impacting its stock price, especially given the heightened sensitivity of investors to executive actions in the current market environment.
- Shareholding Structure Change: Jeffs' sell-off may alter Liquidia's shareholder structure, affecting corporate governance and decision-making processes, particularly as changes in executive shareholding can influence their strategic impact on the company.
- Uncertain Future Outlook: While the sell-off itself does not necessarily indicate a deterioration in the company's fundamentals, the market may adopt a cautious stance towards Liquidia's future development, especially in the context of intense competition in the biopharmaceutical industry.
See More
Form 144: Liquidia (LQDA.US) Executive Plans to Sell $5.11 Million in Common Shares
Share Sale Announcement: Michael Kaseta intends to sell 133,790 shares of Liquidia (LQDA.US) on April 9, with a total market value of approximately $5.11 million.
Reduction in Holdings: Since January 12, 2026, Michael Kaseta has reduced his shareholding in Liquidia by 38,097 shares, valued at around $1.42 million.
See More
Liquidia Chairman Sells 70,234 Shares in Open Market
- Transaction Overview: Liquidia's Chairman Stephen M. Bloch indirectly sold 70,234 shares through multiple open-market transactions valued at approximately $2.53 million, representing 3.02% of his total reported holdings.
- Ownership Analysis: Post-transaction, Bloch retains 65,712 direct shares and 2,188,935 indirect shares, indicating no change in his long-term conviction as the sale did not affect his direct ownership.
- Company Performance Highlights: Liquidia achieved $158.3 million in revenue for 2025, a significant increase from $14 million in 2024, and reported a net income of $14.6 million in Q4, showcasing ongoing profitability improvements.
- Market Reaction and Investment Outlook: Despite Bloch's share sale, Liquidia's stock recently peaked at $46.67, and its YUTREPIA product is recognized as one of the top specialty drug launches in five years, underscoring the company's competitive position and investment appeal.
See More
Liquidia CEO Indirectly Sells 53,300 Shares
- Indirect Share Sale: Liquidia's CEO Roger Jeffs indirectly sold 53,300 shares through Serendipity BioPharma LLC, generating approximately $2.14 million, indicating the company's agility in capital management.
- Updated Holdings: Following this transaction, Liquidia's direct and indirect holdings stand at 1,137,599 and 1,441,934 shares respectively, reflecting management's continued confidence in the company's future direction.
- Strong Yutrepia Sales: Liquidia's dry inhalable treprostinil drug, Yutrepia, achieved an annualized sales figure of $360.4 million in Q4 2025, demonstrating market acceptance that exceeded expectations and enhancing the company's profitability.
- Future Development Potential: Liquidia is developing an extended-release formulation of treprostinil, L606, which is currently in pivotal studies; if successful, this could further solidify its market position in pulmonary hypertension treatments.
See More
Liquidia CEO Indirectly Sells 53,300 Shares, Raising $2.14 Million
- Transaction Overview: Liquidia's CEO Roger Jeffs indirectly sold 53,300 shares through Serendipity BioPharma LLC, generating approximately $2.14 million, indicating a continued preference for liquidity management through indirect vehicles.
- Holding Change Analysis: The 53,300 shares sold represent 2.02% of total holdings and 3.56% of indirect holdings, reflecting a measured reduction while maintaining a substantial direct ownership value of around $47.10 million.
- Transaction Context: This sale was executed under a Rule 10b5-1 plan, classifying it as a routine, pre-scheduled liquidity event rather than a discretionary market-timed action, which reflects management's confidence in the company's future.
- Product Performance Highlights: Liquidia's Yutrepia achieved annualized sales of $360.4 million in Q4 2025, with a net income of $14.6 million, showcasing strong market performance in the pulmonary arterial hypertension treatment space, further bolstering investor confidence.
See More
Liquidia CFO Sells Significant Shares
- Executive Sell-off: On April 9, 2026, Liquidia's CFO and COO, Michael Kaseta, sold 133,789 shares of the company, totaling $5,383,38, which may raise concerns about the company's future outlook among investors.
- Market Reaction: Such executive sell-offs are often perceived as negative signals for stock performance, potentially leading to a decline in investor confidence in Liquidia and affecting its stock price.
- Shareholding Structure Change: Kaseta's sell-off could alter Liquidia's shareholder structure, especially if executive ownership is significant, raising questions about corporate governance and management stability.
- Future Outlook: While the sell-off may cause market fluctuations, investors should continue to monitor Liquidia's fundamentals and future strategic direction to assess its long-term investment value.
See More
Liquidia CEO Sells Shares
- Executive Sell-off: Liquidia's CEO Roger Jeffs sold 25,000 shares on April 9, 2026, which may raise concerns about the company's future prospects, as executive sell-offs are often interpreted as a lack of confidence in the company's performance.
- Market Reaction: This sell-off could lead to a decline in investor trust in Liquidia, potentially impacting its stock price, especially given the heightened sensitivity of investors to executive actions in the current market environment.
- Shareholding Structure Change: Jeffs' sell-off may alter Liquidia's shareholder structure, affecting corporate governance and decision-making processes, particularly as changes in executive shareholding can influence their strategic impact on the company.
- Uncertain Future Outlook: While the sell-off itself does not necessarily indicate a deterioration in the company's fundamentals, the market may adopt a cautious stance towards Liquidia's future development, especially in the context of intense competition in the biopharmaceutical industry.
See More
Form 144: Liquidia (LQDA.US) Executive Plans to Sell $5.11 Million in Common Shares
Share Sale Announcement: Michael Kaseta intends to sell 133,790 shares of Liquidia (LQDA.US) on April 9, with a total market value of approximately $5.11 million.
Reduction in Holdings: Since January 12, 2026, Michael Kaseta has reduced his shareholding in Liquidia by 38,097 shares, valued at around $1.42 million.
See More
Liquidia Chairman Sells 70,234 Shares in Open Market
- Transaction Overview: Liquidia's Chairman Stephen M. Bloch indirectly sold 70,234 shares through multiple open-market transactions valued at approximately $2.53 million, representing 3.02% of his total reported holdings.
- Ownership Analysis: Post-transaction, Bloch retains 65,712 direct shares and 2,188,935 indirect shares, indicating no change in his long-term conviction as the sale did not affect his direct ownership.
- Company Performance Highlights: Liquidia achieved $158.3 million in revenue for 2025, a significant increase from $14 million in 2024, and reported a net income of $14.6 million in Q4, showcasing ongoing profitability improvements.
- Market Reaction and Investment Outlook: Despite Bloch's share sale, Liquidia's stock recently peaked at $46.67, and its YUTREPIA product is recognized as one of the top specialty drug launches in five years, underscoring the company's competitive position and investment appeal.
See More
